LCN2 and injury: The purpose of this report was to evaluate the potential utility of HPLBII-P as a sign of kidney injury and compare its potential with other currently used and well-characterised biomarkers of tubular and glomerular injury such as Cystatin C in urine and plasma [4], urine excretion of albumin, KIM-1 (Kidney Injury Molecule-1) [5], HNL/NGAL (Human Neutrophil Lipocalin/Neutrophil Gelatinase Associated Lipocalin) [6,7], and TIMP-2 (Tissue inhibitor of metalloproteinases 2) [8].